These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12736561)

  • 1. Significance of immunohistochemical assessment of steroid hormone receptor status for breast cancer patients.
    Kurosumi M
    Breast Cancer; 2003; 10(2):97-104. PubMed ID: 12736561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical expression of hormone receptors and the histological characteristics of biochemically hormone receptor negative breast cancers.
    Nishimura R; Saeki T; Ohsumi S; Tani Y; Takashima S
    Breast Cancer; 2007; 14(1):100-4. PubMed ID: 17245003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
    Hussein MR; Abd-Elwahed SR; Abdulwahed AR
    Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical assessment of hormone receptor status using a new scoring system (J-Score) in breast cancer.
    Kurosumi M
    Breast Cancer; 2007; 14(2):189-93. PubMed ID: 17485905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
    Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
    Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer.
    Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F
    BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases.
    Zafrani B; Aubriot MH; Mouret E; De Crémoux P; De Rycke Y; Nicolas A; Boudou E; Vincent-Salomon A; Magdelénat H; Sastre-Garau X
    Histopathology; 2000 Dec; 37(6):536-45. PubMed ID: 11122436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of immunohistochemistry assays and real-time reverse transcription-polymerase chain reaction for analyzing hormone receptor status in human breast carcinoma.
    Oda M; Arihiro K; Kataoka T; Osaki A; Asahara T; Ohdan H
    Pathol Int; 2010 Apr; 60(4):305-15. PubMed ID: 20403033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiated expression of estrogen receptors (ER) and progesterone receptors (PgR) in ductal breast cancers.
    Wojnar A; Drozdz K; Podhorska-Okołów M; Pudełko M; Szuba A; Zabel M; Dziegiel P
    Folia Histochem Cytobiol; 2009; 47(1):55-60. PubMed ID: 19419938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
    Thike AA; Chng MJ; Fook-Chong S; Tan PH
    Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oestrogen receptor negativity as a marker for high-grade ductal carcinoma in situ of the breast.
    Baqai T; Shousha S
    Histopathology; 2003 May; 42(5):440-7. PubMed ID: 12713620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of estrogen and progesterone receptors performed with an antigen-retrieval technique on methacarn-fixed paraffin-embedded breast cancer tissues.
    Oyaizu T; Arita S; Hatano T; Tsubura A
    J Surg Res; 1996 Jan; 60(1):69-73. PubMed ID: 8592434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.
    Neubauer H; Clare SE; Wozny W; Schwall GP; Poznanovic S; Stegmann W; Vogel U; Sotlar K; Wallwiener D; Kurek R; Fehm T; Cahill MA
    Breast Cancer Res; 2008; 10(5):R85. PubMed ID: 18922159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of serial semithin frozen sections to evaluate the co-localization of estrogen receptors and progesterone receptors in cells of breast cancer tissues.
    Kudo A; Fukushima H; Kawakami H; Matsuda M; Goya T; Hirano H
    J Histochem Cytochem; 1996 Jun; 44(6):615-20. PubMed ID: 8666746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
    Yu KD; Jiang YZ; Hao S; Shao ZM
    BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive intraductal component (EIC) and estrogen receptor (ER) status in breast cancer.
    Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Oura S; Sakurai T
    Pathol Int; 1998 Jun; 48(6):440-7. PubMed ID: 9702856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
    Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
    Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oestrogen receptor-negative/progesterone receptor-positive phenotype of invasive breast carcinoma in Japan: re-evaluated using immunohistochemical staining.
    Kuroda H; Muroi N; Hayashi M; Harada O; Hoshi K; Fukuma E; Abe A; Kubota K; Imai Y
    Breast Cancer; 2019 Mar; 26(2):249-254. PubMed ID: 30066060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.